Nektar Therapeutics (NKTR) Non-Current Debt (2012 - 2020)

Nektar Therapeutics' Non-Current Debt history runs 9 years deep, the most recent figure standing at $254.8 million for Q1 2020.

• In Q1 2020, Non-Current Debt rose 3.0% year-over-year to $254.8 million; the TTM figure through Mar 2020 stood at $254.8 million (up 3.0% YoY), while the FY2018 annual figure was $247.0 million, up 0.71% from the prior year.
• Non-Current Debt for Q1 2020 stood at $254.8 million, up from $248.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $254.8 million in Q1 2020, with the low at $242.1 million in Q1 2016.
• The 5-year median for Non-Current Debt is $245.4 million (2017), against an average of $245.8 million.
• The sharpest annual moves came in 2016 and 2019: Non-Current Debt jumped 94.05% in 2016, then rose 0.71% in 2019.
• Nektar Therapeutics' Non-Current Debt stood at $243.5 million in 2016, then climbed by 0.72% to $245.2 million in 2017, then climbed by 0.71% to $247.0 million in 2018, then rose by 0.53% to $248.3 million in 2019, then increased by 2.64% to $254.8 million in 2020.
• Business Quant data shows NKTR's Non-Current Debt at $254.8 million in Q1 2020, $248.3 million in Q3 2019, and $247.8 million in Q2 2019.